Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
56.12
+0.64 (1.15%)
Dec 20, 2024, 4:00 PM EST - Market closed
Rhythm Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 112.53 | 77.43 | 23.64 | 3.15 | - | - | Upgrade
|
| Revenue Growth (YoY) | 81.55% | 227.56% | 649.46% | - | - | - | Upgrade
|
| Cost of Revenue | 12.81 | 9.3 | 2.13 | 0.6 | - | - | Upgrade
|
| Gross Profit | 99.72 | 68.13 | 21.51 | 2.56 | - | - | Upgrade
|
| Selling, General & Admin | 138.55 | 117.53 | 92.03 | 68.49 | 46.13 | 36.55 | Upgrade
|
| Research & Development | 226.68 | 134.95 | 108.63 | 104.13 | 90.45 | 109.45 | Upgrade
|
| Operating Expenses | 365.23 | 252.48 | 200.66 | 172.61 | 136.58 | 146 | Upgrade
|
| Operating Income | -265.51 | -184.36 | -179.16 | -170.06 | -136.58 | -146 | Upgrade
|
| Interest Expense | -19.71 | -13.89 | -5.2 | - | - | - | Upgrade
|
| Interest & Investment Income | 15.02 | 13.95 | 4.03 | 0.45 | 2.58 | 5.27 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.59 | 0.19 | 0.25 | 100 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -258.31 | -184.11 | -180.08 | -69.61 | -134 | -140.73 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -1.04 | - | - | - | Upgrade
|
| Pretax Income | -258.31 | -184.11 | -181.12 | -69.61 | -134 | -140.73 | Upgrade
|
| Income Tax Expense | 0.63 | 0.56 | - | - | - | - | Upgrade
|
| Net Income | -258.94 | -184.68 | -181.12 | -69.61 | -134 | -140.73 | Upgrade
|
| Preferred Dividends & Other Adjustments | 2.63 | - | - | - | - | - | Upgrade
|
| Net Income to Common | -261.57 | -184.68 | -181.12 | -69.61 | -134 | -140.73 | Upgrade
|
| Shares Outstanding (Basic) | 60 | 58 | 52 | 50 | 44 | 36 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 58 | 52 | 50 | 44 | 36 | Upgrade
|
| Shares Change (YoY) | 6.06% | 10.65% | 5.08% | 12.40% | 21.15% | 17.48% | Upgrade
|
| EPS (Basic) | -4.33 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | Upgrade
|
| EPS (Diluted) | -4.33 | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 | Upgrade
|
| Free Cash Flow | -124.42 | -136.2 | -173.71 | -146.44 | -122.19 | -126.14 | Upgrade
|
| Free Cash Flow Per Share | -2.06 | -2.36 | -3.33 | -2.95 | -2.77 | -3.46 | Upgrade
|
| Gross Margin | 88.61% | 87.99% | 90.98% | 81.01% | - | - | Upgrade
|
| Operating Margin | -235.95% | -238.10% | -757.92% | -5391.85% | - | - | Upgrade
|
| Profit Margin | -232.45% | -238.52% | -766.22% | -2207.10% | - | - | Upgrade
|
| Free Cash Flow Margin | -110.56% | -175.91% | -734.87% | -4642.90% | - | - | Upgrade
|
| EBITDA | -263.92 | -182.6 | -177.49 | -168.9 | -135.89 | -145.17 | Upgrade
|
| EBITDA Margin | -234.53% | -235.83% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.6 | 1.76 | 1.67 | 1.16 | 0.69 | 0.83 | Upgrade
|
| EBIT | -265.51 | -184.36 | -179.16 | -170.06 | -136.58 | -146 | Upgrade
|
| EBIT Margin | -235.95% | -238.10% | - | - | - | - | Upgrade
|
| Revenue as Reported | 112.53 | 77.43 | 23.64 | 3.15 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.